Jie Yang
Jie Yang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Chang-Hong Zong
Department of Human Anatomy, Histology and embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China
4 shared publicationsLing Chang
Xi'an Electronic Engineering Research Institute, Xi'an, Shaanxi 710100, China
3 shared publicationsXiao-Dan Hu
Department of Human Anatomy, Histology and Embryology, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China
3 shared publicationsYi-Hua Qian
Department of Human Anatomy, Histology and embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China
3 shared publicationsChang Yang
School of Stomatology, Lanzhou University, Lanzhou, China
2 shared publicationsGai-Feng Feng
Department of Human Anatomy, Histology and embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China
2 shared publications
Latest Publications
- 16 February 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31 (4) , 106160
Protection of Vasoactive Intestinal Peptide on the Blood-Brain Barrier Dysfunction Induced by Focal Cerebral Ischemia in Rats
- 16 February 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31 (4) , 106160
Protection of Vasoactive Intestinal Peptide on the Blood-Brain Barrier Dysfunction Induced by Focal Cerebral Ischemia in Rats
- 1 August 2021
- Published by Elsevier in Brain Research Bulletin
- Vol. 173, 97-107
Mild therapeutic hypothermia improves neurological outcomes in a rat model of cardiac arrest
- 1 August 2021
- Published by Elsevier in Brain Research Bulletin
- Vol. 173, 97-107
Mild therapeutic hypothermia improves neurological outcomes in a rat model of cardiac arrest
- Open Access
- 30 May 2019
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 23 (6) , 380-386
Relationship Between Genetic Polymorphisms of the TNF Gene and Hallux Valgus Susceptibility
Background: Hallux valgus (HV) is a type of forefoot deformity affecting ∼23% of adults. Previous studies have shown that HV is highly heritable. Tumor necrosis factor ( TNF ) is an important proinflammatory cytokine involved in bone remodeling and plays essential roles in osteoarthritis and chronic inflammatory bone diseases, including HV. Methods: A total of 1,788 Chinese women comprising 637 HV subjects and 1,151 controls were recruited. Twelve single nucleotide polymorphisms (SNPs) located in TNF and its promoter regions were selected and genotyped. Genetic association analyses were performed to investigate potential susceptibility SNPs. Bioinformatic and expression quantitative trait loci (eQTL) analyses were conducted to examine the functional consequences of the SNPs identified as being significantly associated with HV. Results: SNP rs1800629, which is located at the 5′ end of the promoter region of TNF , was identified as significantly associated with HV status in Chinese women (OR = 0.56, p = 2.12 × 10 −6 ). Bioinformatic analyses using RegulomeDB indicated that this SNP has important functional significance, but subsequent eQTL analyses did not identify a significant association between rs1800629 and TNF gene expression. In addition, 26 genes with cis-eQTL for rs1800629 were identified. Conclusions: This study identified a susceptibility SNP for HV located within the promoter region of the TNF gene. Bioinformatic and eQTL analyses linked this SNP to 26 genes but not to TNF . Functional studies are needed to more fully characterize the effects of this SNP.
- 30 May 2019
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 23 (6) , 380-386
Open AccessRelationship Between Genetic Polymorphisms of the TNF Gene and Hallux Valgus Susceptibility
Background: Hallux valgus (HV) is a type of forefoot deformity affecting ∼23% of adults. Previous studies have shown that HV is highly heritable. Tumor necrosis factor ( TNF ) is an important proinflammatory cytokine involved in bone remodeling and plays essential roles in osteoarthritis and chronic inflammatory bone diseases, including HV. Methods: A total of 1,788 Chinese women comprising 637 HV subjects and 1,151 controls were recruited. Twelve single nucleotide polymorphisms (SNPs) located in TNF and its promoter regions were selected and genotyped. Genetic association analyses were performed to investigate potential susceptibility SNPs. Bioinformatic and expression quantitative trait loci (eQTL) analyses were conducted to examine the functional consequences of the SNPs identified as being significantly associated with HV. Results: SNP rs1800629, which is located at the 5′ end of the promoter region of TNF , was identified as significantly associated with HV status in Chinese women (OR = 0.56, p = 2.12 × 10 −6 ). Bioinformatic analyses using RegulomeDB indicated that this SNP has important functional significance, but subsequent eQTL analyses did not identify a significant association between rs1800629 and TNF gene expression. In addition, 26 genes with cis-eQTL for rs1800629 were identified. Conclusions: This study identified a susceptibility SNP for HV located within the promoter region of the TNF gene. Bioinformatic and eQTL analyses linked this SNP to 26 genes but not to TNF . Functional studies are needed to more fully characterize the effects of this SNP.
- 1 November 2015
- Published by Elsevier in Brain Research
- Vol. 1625, 189-197
Vasoactive intestinal peptide administration after stroke in rats enhances neurogenesis and improves neurological function
- 1 November 2015
- Published by Elsevier in Brain Research
- Vol. 1625, 189-197
Vasoactive intestinal peptide administration after stroke in rats enhances neurogenesis and improves neurological function
- 1 June 2011
- Published by Elsevier in Brain Research
- Vol. 1398, 94-101
Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats
- 1 June 2011
- Published by Elsevier in Brain Research
- Vol. 1398, 94-101
Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats
- 1 April 2009
- Vol. 29 (4) , 619-22
[Vasoactive intestinal peptide enhances angiogenesis after focal cerebral ischemia].
To investigate the effect of vasoactive intestinal peptide (VIP) on angiogenesis after focal cerebral ischemia. Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 120 min in adult SD rats with intracerebroventricular VIP administration at the beginning of reperfusion. Immunohistochemistry was performed to assay BrdU immunoreactive endothelial cells, expressions of VEGF, flt-1 and flk-1 in the ischemic zone, and the protein expressions of vascular endothelial growth factor (VEGF) in the brain was measured using Western blotting. Immunohistochemical staining revealed significantly increased BrdU immunoreactive endothelial cells on the margins of the ischemic lesion in rats treated with VIP as compared with that in the control rats (P<0.05). VIP significantly increased the number of VEGF immunoreactive cells and flt-1- and flk-1-positive endothelial cells in comparison with the control group (P<0.01). Western blotting showed that VIP treatment resulted in significantly increased VEGF protein level in the ipsilateral hemisphere (P<0.05). VIP enhances angiogenesis in the ischemic brain by increasing the expressions of VEGF in the brain tissue and its receptors flt-1 and flk-1 in the endothelial cells.
- 1 April 2009
- Vol. 29 (4) , 619-22
[Vasoactive intestinal peptide enhances angiogenesis after focal cerebral ischemia].
To investigate the effect of vasoactive intestinal peptide (VIP) on angiogenesis after focal cerebral ischemia. Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 120 min in adult SD rats with intracerebroventricular VIP administration at the beginning of reperfusion. Immunohistochemistry was performed to assay BrdU immunoreactive endothelial cells, expressions of VEGF, flt-1 and flk-1 in the ischemic zone, and the protein expressions of vascular endothelial growth factor (VEGF) in the brain was measured using Western blotting. Immunohistochemical staining revealed significantly increased BrdU immunoreactive endothelial cells on the margins of the ischemic lesion in rats treated with VIP as compared with that in the control rats (P<0.05). VIP significantly increased the number of VEGF immunoreactive cells and flt-1- and flk-1-positive endothelial cells in comparison with the control group (P<0.01). Western blotting showed that VIP treatment resulted in significantly increased VEGF protein level in the ipsilateral hemisphere (P<0.05). VIP enhances angiogenesis in the ischemic brain by increasing the expressions of VEGF in the brain tissue and its receptors flt-1 and flk-1 in the endothelial cells.
- 1 December 2007
- Vol. 27 (12) , 1801-4
[Neuroprotective effects of vasoactive intestinal peptide against rat cerebral ischemia].
To explore the neuroprotective effect of vasoactive intestinal peptide (VIP) in rat ischemic brain injury. VIP was administered via intracerebroventricular injection in SD rats prior to focal cerebral ischemia by intraluminal occlusion of the middle cerebral artery. The infarct volume was assessed with TTC staining, and immunohistochemistry was performed to analyze the S100beta expression in the cerebral tissue, with the serum concentrations of S100beta detected by double-antibody sandwich enzyme-linked immunosorbent assay. After VIP injection, the relative infarct volume in the rats with cerebral ischemia was significantly reduced by 32.3% as compared with the volume in the control group on day 1 (P<0.05), and the number of S100beta-positive cells was significantly decreased in the cerebral tissue (P<0.05). The injection also resulted in significantly decreased serum S100beta concentrations in the rats (P<0.05). VIP injection can reduce the infarct volume in rats with focal cerebral ischemia, suggesting the neuroprotective effect of VIP in brain ischemia possibly by reducing S100beta overexpression.
- 1 December 2007
- Vol. 27 (12) , 1801-4
[Neuroprotective effects of vasoactive intestinal peptide against rat cerebral ischemia].
To explore the neuroprotective effect of vasoactive intestinal peptide (VIP) in rat ischemic brain injury. VIP was administered via intracerebroventricular injection in SD rats prior to focal cerebral ischemia by intraluminal occlusion of the middle cerebral artery. The infarct volume was assessed with TTC staining, and immunohistochemistry was performed to analyze the S100beta expression in the cerebral tissue, with the serum concentrations of S100beta detected by double-antibody sandwich enzyme-linked immunosorbent assay. After VIP injection, the relative infarct volume in the rats with cerebral ischemia was significantly reduced by 32.3% as compared with the volume in the control group on day 1 (P<0.05), and the number of S100beta-positive cells was significantly decreased in the cerebral tissue (P<0.05). The injection also resulted in significantly decreased serum S100beta concentrations in the rats (P<0.05). VIP injection can reduce the infarct volume in rats with focal cerebral ischemia, suggesting the neuroprotective effect of VIP in brain ischemia possibly by reducing S100beta overexpression.